Search
CanSino Secures Drug Registration Certificate for 13-valent Pneumococcal Conjugate Vaccine
3 week ago /
Read about 0 minute
Author：小编
CanSino Biologics has proudly announced the receipt of the Drug Registration Certificate for its 13-valent Pneumococcal Conjugate Vaccine, issued by the National Medical Products Administration. This milestone marks the company's inaugural certified product within its pneumococcal vaccine portfolio, solidifying its position and setting a strong foundation for future advancements in high-valent pneumococcal conjugate vaccines.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
